-
Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) division and reported third-quarter earnings, with sales reaching US$26.33 million and a net loss of US$30.41 million for the period ended September 30, 2025.
-
This move marks a business realignment to concentrate on the core surgical segment, with management expecting THP wind-down costs to conclude by the end of 2025 and further resource shifts to support main operations.
-
We’ll explore how the decision to exit THP and focus on core surgical products influences Sanara MedTech’s investment outlook.
AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
To be a Sanara MedTech shareholder, you need to believe in the potential of its core surgical segment to drive future growth and profitability, especially as the company pivots away from digital health. The decision to discontinue the THP division directly addresses one of the short-term risks, persistent net losses and resource drag, while sharpening focus on the surgical business, which remains the primary catalyst for near-term improvement. The move does not materially change competitive or market risks, but it may impact resource allocation and operational priorities in the coming quarters. Among recent announcements, the company’s accelerated growth in its distributor and healthcare facility network is particularly relevant. This expanded reach could support higher sales volumes for Sanara’s proprietary surgical products and help offset both the transitional costs of winding down THP and the ongoing pressure from limited portfolio diversification. But on the flip side, investors should be aware that Sanara’s continued heavy focus on a narrow range of surgical wound care products means that…
Read the full narrative on Sanara MedTech (it’s free!)
Sanara MedTech’s outlook anticipates $144.9 million in revenue and $1.9 million in earnings by 2028. This scenario is based on a 14.2% annual revenue growth rate and an $11.8 million increase in earnings from the current -$9.9 million.
Uncover how Sanara MedTech’s forecasts yield a $41.00 fair value, a 90% upside to its current price.
Three distinct fair value estimates from the Simply Wall St Community fall between US$18.41 and US$41. With investors split on valuation, pay close attention to ongoing net losses and how business realignment could affect future earnings.